This deal adds two more siRNA candidates to GSK’s pipeline, which is expanding as the company looks to offset the impact of ...
AbbVie has announced plans to invest $380m to construct two new active pharmaceutical ingredient (API) manufacturing ...
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new framework to spur the development of therapies for ultra-rare ...
Beren Therapeutics has received the US (FDA acceptance to review its NDA for adrabetadex, an investigational therapy targeting intracellular cholesterol trafficking for infantile-onset NPC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results